Actively Recruiting

Phase 1
Age: 18Years - 80Years
All Genders
NCT06435910

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-24

10

Participants Needed

2

Research Sites

189 weeks

Total Duration

On this page

Sponsors

S

Shenzhen Geno-Immune Medical Institute

Lead Sponsor

T

The No.2 Clinical Hospital of the Ministry of Health

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.

CONDITIONS

Official Title

Engineered Dendritic Cell Vaccines for Multiple Myeloma

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female subjects with multiple myeloma or plasmacytoma
  • Very good partial or complete remission after prior combination therapies
  • Expected survival longer than 12 weeks
  • Adequate venous access for blood withdrawal or apheresis with no contraindications
  • Voluntary informed consent with willingness to continue follow up
Not Eligible

You will not qualify if you...

  • Pregnant or lactating women
  • Uncontrolled active infection
  • HIV or active hepatitis B or hepatitis C infection
  • Concurrent use of systemic steroids; inhaled steroids are allowed

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China, 518000

Actively Recruiting

2

The Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health

Vladivostok, Russia, 690105

Actively Recruiting

Loading map...

Research Team

L

Lung-Ji Chang, ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Engineered Dendritic Cell Vaccines for Multiple Myeloma | DecenTrialz